Global Novel Coronavirus Inactivated Vaccine Market Growth 2022-2028
The report requires updating with new data and is sent in 48 hours after order is placed.
The global market for Novel Coronavirus Inactivated Vaccine is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
The APAC Novel Coronavirus Inactivated Vaccine market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The United States Novel Coronavirus Inactivated Vaccine market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The Europe Novel Coronavirus Inactivated Vaccine market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The China Novel Coronavirus Inactivated Vaccine market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
Global key Novel Coronavirus Inactivated Vaccine players cover Inovio Pharmaceuticals, Moderna, GlaxoSmithKine, Pfizer and Johnson&Johnson, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
Report Coverage
This latest report provides a deep insight into the global Novel Coronavirus Inactivated Vaccine market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.
This report aims to provide a comprehensive picture of the global Novel Coronavirus Inactivated Vaccine market, with both quantitative and qualitative data, to help readers understand how the Novel Coronavirus Inactivated Vaccine market scenario changed across the globe during the pandemic and Russia-Ukraine War.
The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions and volume in K Units.
Market Segmentation:
The study segments the Novel Coronavirus Inactivated Vaccine market and forecasts the market size by Type (Adult and Child,), by Application (Hospital and Clinic.), and region (APAC, Americas, Europe, and Middle East & Africa).
Segmentation by type
Chapter 1: Scope of Novel Coronavirus Inactivated Vaccine, Research Methodology, etc.
Chapter 2: Executive Summary, global Novel Coronavirus Inactivated Vaccine market size (sales and revenue) and CAGR, Novel Coronavirus Inactivated Vaccine market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Novel Coronavirus Inactivated Vaccine sales, revenue, average price, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Novel Coronavirus Inactivated Vaccine sales and revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, sales segment by country, by type, and type.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Novel Coronavirus Inactivated Vaccine market size forecast by region, by country, by type, and application.
Chapter 13: Comprehensive company profiles of the leading players, including Inovio Pharmaceuticals, Moderna, GlaxoSmithKine, Pfizer, Johnson&Johnson, Heat Biologics, Sanofi, Beijing Institute of Biological Products Co., Ltd and Beijing Kexing Zhongwei Biotechnology Co., Ltd, etc.
Chapter 14: Research Findings and Conclusion
The global market for Novel Coronavirus Inactivated Vaccine is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
The APAC Novel Coronavirus Inactivated Vaccine market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The United States Novel Coronavirus Inactivated Vaccine market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The Europe Novel Coronavirus Inactivated Vaccine market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The China Novel Coronavirus Inactivated Vaccine market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
Global key Novel Coronavirus Inactivated Vaccine players cover Inovio Pharmaceuticals, Moderna, GlaxoSmithKine, Pfizer and Johnson&Johnson, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
Report Coverage
This latest report provides a deep insight into the global Novel Coronavirus Inactivated Vaccine market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.
This report aims to provide a comprehensive picture of the global Novel Coronavirus Inactivated Vaccine market, with both quantitative and qualitative data, to help readers understand how the Novel Coronavirus Inactivated Vaccine market scenario changed across the globe during the pandemic and Russia-Ukraine War.
The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions and volume in K Units.
Market Segmentation:
The study segments the Novel Coronavirus Inactivated Vaccine market and forecasts the market size by Type (Adult and Child,), by Application (Hospital and Clinic.), and region (APAC, Americas, Europe, and Middle East & Africa).
Segmentation by type
- Adult
- Child
- Hospital
- Clinic
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Inovio Pharmaceuticals
- Moderna
- GlaxoSmithKine
- Pfizer
- Johnson&Johnson
- Heat Biologics
- Sanofi
- Beijing Institute of Biological Products Co., Ltd
- Beijing Kexing Zhongwei Biotechnology Co., Ltd
- Shanghai Pharmaceutical CanSino Biopharmaceutical Co., Ltd
- Wuhan Institute of Biological Products Co., Ltd
Chapter 1: Scope of Novel Coronavirus Inactivated Vaccine, Research Methodology, etc.
Chapter 2: Executive Summary, global Novel Coronavirus Inactivated Vaccine market size (sales and revenue) and CAGR, Novel Coronavirus Inactivated Vaccine market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Novel Coronavirus Inactivated Vaccine sales, revenue, average price, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Novel Coronavirus Inactivated Vaccine sales and revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, sales segment by country, by type, and type.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Novel Coronavirus Inactivated Vaccine market size forecast by region, by country, by type, and application.
Chapter 13: Comprehensive company profiles of the leading players, including Inovio Pharmaceuticals, Moderna, GlaxoSmithKine, Pfizer, Johnson&Johnson, Heat Biologics, Sanofi, Beijing Institute of Biological Products Co., Ltd and Beijing Kexing Zhongwei Biotechnology Co., Ltd, etc.
Chapter 14: Research Findings and Conclusion
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Novel Coronavirus Inactivated Vaccine Annual Sales 2017-2028
2.1.2 World Current & Future Analysis for Novel Coronavirus Inactivated Vaccine by Geographic Region, 2017, 2022 & 2028
2.1.3 World Current & Future Analysis for Novel Coronavirus Inactivated Vaccine by Country/Region, 2017, 2022 & 2028
2.2 Novel Coronavirus Inactivated Vaccine Segment by Type
2.2.1 Adult
2.2.2 Child
2.3 Novel Coronavirus Inactivated Vaccine Sales by Type
2.3.1 Global Novel Coronavirus Inactivated Vaccine Sales Market Share by Type (2017-2022)
2.3.2 Global Novel Coronavirus Inactivated Vaccine Revenue and Market Share by Type (2017-2022)
2.3.3 Global Novel Coronavirus Inactivated Vaccine Sale Price by Type (2017-2022)
2.4 Novel Coronavirus Inactivated Vaccine Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.5 Novel Coronavirus Inactivated Vaccine Sales by Application
2.5.1 Global Novel Coronavirus Inactivated Vaccine Sale Market Share by Application (2017-2022)
2.5.2 Global Novel Coronavirus Inactivated Vaccine Revenue and Market Share by Application (2017-2022)
2.5.3 Global Novel Coronavirus Inactivated Vaccine Sale Price by Application (2017-2022)
3 GLOBAL NOVEL CORONAVIRUS INACTIVATED VACCINE BY COMPANY
3.1 Global Novel Coronavirus Inactivated Vaccine Breakdown Data by Company
3.1.1 Global Novel Coronavirus Inactivated Vaccine Annual Sales by Company (2020-2022)
3.1.2 Global Novel Coronavirus Inactivated Vaccine Sales Market Share by Company (2020-2022)
3.2 Global Novel Coronavirus Inactivated Vaccine Annual Revenue by Company (2020-2022)
3.2.1 Global Novel Coronavirus Inactivated Vaccine Revenue by Company (2020-2022)
3.2.2 Global Novel Coronavirus Inactivated Vaccine Revenue Market Share by Company (2020-2022)
3.3 Global Novel Coronavirus Inactivated Vaccine Sale Price by Company
3.4 Key Manufacturers Novel Coronavirus Inactivated Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Novel Coronavirus Inactivated Vaccine Product Location Distribution
3.4.2 Players Novel Coronavirus Inactivated Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR NOVEL CORONAVIRUS INACTIVATED VACCINE BY GEOGRAPHIC REGION
4.1 World Historic Novel Coronavirus Inactivated Vaccine Market Size by Geographic Region (2017-2022)
4.1.1 Global Novel Coronavirus Inactivated Vaccine Annual Sales by Geographic Region (2017-2022)
4.1.2 Global Novel Coronavirus Inactivated Vaccine Annual Revenue by Geographic Region
4.2 World Historic Novel Coronavirus Inactivated Vaccine Market Size by Country/Region (2017-2022)
4.2.1 Global Novel Coronavirus Inactivated Vaccine Annual Sales by Country/Region (2017-2022)
4.2.2 Global Novel Coronavirus Inactivated Vaccine Annual Revenue by Country/Region
4.3 Americas Novel Coronavirus Inactivated Vaccine Sales Growth
4.4 APAC Novel Coronavirus Inactivated Vaccine Sales Growth
4.5 Europe Novel Coronavirus Inactivated Vaccine Sales Growth
4.6 Middle East & Africa Novel Coronavirus Inactivated Vaccine Sales Growth
5 AMERICAS
5.1 Americas Novel Coronavirus Inactivated Vaccine Sales by Country
5.1.1 Americas Novel Coronavirus Inactivated Vaccine Sales by Country (2017-2022)
5.1.2 Americas Novel Coronavirus Inactivated Vaccine Revenue by Country (2017-2022)
5.2 Americas Novel Coronavirus Inactivated Vaccine Sales by Type
5.3 Americas Novel Coronavirus Inactivated Vaccine Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Novel Coronavirus Inactivated Vaccine Sales by Region
6.1.1 APAC Novel Coronavirus Inactivated Vaccine Sales by Region (2017-2022)
6.1.2 APAC Novel Coronavirus Inactivated Vaccine Revenue by Region (2017-2022)
6.2 APAC Novel Coronavirus Inactivated Vaccine Sales by Type
6.3 APAC Novel Coronavirus Inactivated Vaccine Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Novel Coronavirus Inactivated Vaccine by Country
7.1.1 Europe Novel Coronavirus Inactivated Vaccine Sales by Country (2017-2022)
7.1.2 Europe Novel Coronavirus Inactivated Vaccine Revenue by Country (2017-2022)
7.2 Europe Novel Coronavirus Inactivated Vaccine Sales by Type
7.3 Europe Novel Coronavirus Inactivated Vaccine Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Novel Coronavirus Inactivated Vaccine by Country
8.1.1 Middle East & Africa Novel Coronavirus Inactivated Vaccine Sales by Country (2017-2022)
8.1.2 Middle East & Africa Novel Coronavirus Inactivated Vaccine Revenue by Country (2017-2022)
8.2 Middle East & Africa Novel Coronavirus Inactivated Vaccine Sales by Type
8.3 Middle East & Africa Novel Coronavirus Inactivated Vaccine Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Novel Coronavirus Inactivated Vaccine
10.3 Manufacturing Process Analysis of Novel Coronavirus Inactivated Vaccine
10.4 Industry Chain Structure of Novel Coronavirus Inactivated Vaccine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Novel Coronavirus Inactivated Vaccine Distributors
11.3 Novel Coronavirus Inactivated Vaccine Customer
12 WORLD FORECAST REVIEW FOR NOVEL CORONAVIRUS INACTIVATED VACCINE BY GEOGRAPHIC REGION
12.1 Global Novel Coronavirus Inactivated Vaccine Market Size Forecast by Region
12.1.1 Global Novel Coronavirus Inactivated Vaccine Forecast by Region (2023-2028)
12.1.2 Global Novel Coronavirus Inactivated Vaccine Annual Revenue Forecast by Region (2023-2028)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Novel Coronavirus Inactivated Vaccine Forecast by Type
12.7 Global Novel Coronavirus Inactivated Vaccine Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Inovio Pharmaceuticals
13.1.1 Inovio Pharmaceuticals Company Information
13.1.2 Inovio Pharmaceuticals Novel Coronavirus Inactivated Vaccine Product Offered
13.1.3 Inovio Pharmaceuticals Novel Coronavirus Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.1.4 Inovio Pharmaceuticals Main Business Overview
13.1.5 Inovio Pharmaceuticals Latest Developments
13.2 Moderna
13.2.1 Moderna Company Information
13.2.2 Moderna Novel Coronavirus Inactivated Vaccine Product Offered
13.2.3 Moderna Novel Coronavirus Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.2.4 Moderna Main Business Overview
13.2.5 Moderna Latest Developments
13.3 GlaxoSmithKine
13.3.1 GlaxoSmithKine Company Information
13.3.2 GlaxoSmithKine Novel Coronavirus Inactivated Vaccine Product Offered
13.3.3 GlaxoSmithKine Novel Coronavirus Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.3.4 GlaxoSmithKine Main Business Overview
13.3.5 GlaxoSmithKine Latest Developments
13.4 Pfizer
13.4.1 Pfizer Company Information
13.4.2 Pfizer Novel Coronavirus Inactivated Vaccine Product Offered
13.4.3 Pfizer Novel Coronavirus Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.4.4 Pfizer Main Business Overview
13.4.5 Pfizer Latest Developments
13.5 Johnson&Johnson
13.5.1 Johnson&Johnson Company Information
13.5.2 Johnson&Johnson Novel Coronavirus Inactivated Vaccine Product Offered
13.5.3 Johnson&Johnson Novel Coronavirus Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.5.4 Johnson&Johnson Main Business Overview
13.5.5 Johnson&Johnson Latest Developments
13.6 Heat Biologics
13.6.1 Heat Biologics Company Information
13.6.2 Heat Biologics Novel Coronavirus Inactivated Vaccine Product Offered
13.6.3 Heat Biologics Novel Coronavirus Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.6.4 Heat Biologics Main Business Overview
13.6.5 Heat Biologics Latest Developments
13.7 Sanofi
13.7.1 Sanofi Company Information
13.7.2 Sanofi Novel Coronavirus Inactivated Vaccine Product Offered
13.7.3 Sanofi Novel Coronavirus Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.7.4 Sanofi Main Business Overview
13.7.5 Sanofi Latest Developments
13.8 Beijing Institute of Biological Products Co., Ltd
13.8.1 Beijing Institute of Biological Products Co., Ltd Company Information
13.8.2 Beijing Institute of Biological Products Co., Ltd Novel Coronavirus Inactivated Vaccine Product Offered
13.8.3 Beijing Institute of Biological Products Co., Ltd Novel Coronavirus Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.8.4 Beijing Institute of Biological Products Co., Ltd Main Business Overview
13.8.5 Beijing Institute of Biological Products Co., Ltd Latest Developments
13.9 Beijing Kexing Zhongwei Biotechnology Co., Ltd
13.9.1 Beijing Kexing Zhongwei Biotechnology Co., Ltd Company Information
13.9.2 Beijing Kexing Zhongwei Biotechnology Co., Ltd Novel Coronavirus Inactivated Vaccine Product Offered
13.9.3 Beijing Kexing Zhongwei Biotechnology Co., Ltd Novel Coronavirus Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.9.4 Beijing Kexing Zhongwei Biotechnology Co., Ltd Main Business Overview
13.9.5 Beijing Kexing Zhongwei Biotechnology Co., Ltd Latest Developments
13.10 Shanghai Pharmaceutical CanSino Biopharmaceutical Co., Ltd
13.10.1 Shanghai Pharmaceutical CanSino Biopharmaceutical Co., Ltd Company Information
13.10.2 Shanghai Pharmaceutical CanSino Biopharmaceutical Co., Ltd Novel Coronavirus Inactivated Vaccine Product Offered
13.10.3 Shanghai Pharmaceutical CanSino Biopharmaceutical Co., Ltd Novel Coronavirus Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.10.4 Shanghai Pharmaceutical CanSino Biopharmaceutical Co., Ltd Main Business Overview
13.10.5 Shanghai Pharmaceutical CanSino Biopharmaceutical Co., Ltd Latest Developments
13.11 Wuhan Institute of Biological Products Co., Ltd
13.11.1 Wuhan Institute of Biological Products Co., Ltd Company Information
13.11.2 Wuhan Institute of Biological Products Co., Ltd Novel Coronavirus Inactivated Vaccine Product Offered
13.11.3 Wuhan Institute of Biological Products Co., Ltd Novel Coronavirus Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.11.4 Wuhan Institute of Biological Products Co., Ltd Main Business Overview
13.11.5 Wuhan Institute of Biological Products Co., Ltd Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Novel Coronavirus Inactivated Vaccine Annual Sales 2017-2028
2.1.2 World Current & Future Analysis for Novel Coronavirus Inactivated Vaccine by Geographic Region, 2017, 2022 & 2028
2.1.3 World Current & Future Analysis for Novel Coronavirus Inactivated Vaccine by Country/Region, 2017, 2022 & 2028
2.2 Novel Coronavirus Inactivated Vaccine Segment by Type
2.2.1 Adult
2.2.2 Child
2.3 Novel Coronavirus Inactivated Vaccine Sales by Type
2.3.1 Global Novel Coronavirus Inactivated Vaccine Sales Market Share by Type (2017-2022)
2.3.2 Global Novel Coronavirus Inactivated Vaccine Revenue and Market Share by Type (2017-2022)
2.3.3 Global Novel Coronavirus Inactivated Vaccine Sale Price by Type (2017-2022)
2.4 Novel Coronavirus Inactivated Vaccine Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.5 Novel Coronavirus Inactivated Vaccine Sales by Application
2.5.1 Global Novel Coronavirus Inactivated Vaccine Sale Market Share by Application (2017-2022)
2.5.2 Global Novel Coronavirus Inactivated Vaccine Revenue and Market Share by Application (2017-2022)
2.5.3 Global Novel Coronavirus Inactivated Vaccine Sale Price by Application (2017-2022)
3 GLOBAL NOVEL CORONAVIRUS INACTIVATED VACCINE BY COMPANY
3.1 Global Novel Coronavirus Inactivated Vaccine Breakdown Data by Company
3.1.1 Global Novel Coronavirus Inactivated Vaccine Annual Sales by Company (2020-2022)
3.1.2 Global Novel Coronavirus Inactivated Vaccine Sales Market Share by Company (2020-2022)
3.2 Global Novel Coronavirus Inactivated Vaccine Annual Revenue by Company (2020-2022)
3.2.1 Global Novel Coronavirus Inactivated Vaccine Revenue by Company (2020-2022)
3.2.2 Global Novel Coronavirus Inactivated Vaccine Revenue Market Share by Company (2020-2022)
3.3 Global Novel Coronavirus Inactivated Vaccine Sale Price by Company
3.4 Key Manufacturers Novel Coronavirus Inactivated Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Novel Coronavirus Inactivated Vaccine Product Location Distribution
3.4.2 Players Novel Coronavirus Inactivated Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR NOVEL CORONAVIRUS INACTIVATED VACCINE BY GEOGRAPHIC REGION
4.1 World Historic Novel Coronavirus Inactivated Vaccine Market Size by Geographic Region (2017-2022)
4.1.1 Global Novel Coronavirus Inactivated Vaccine Annual Sales by Geographic Region (2017-2022)
4.1.2 Global Novel Coronavirus Inactivated Vaccine Annual Revenue by Geographic Region
4.2 World Historic Novel Coronavirus Inactivated Vaccine Market Size by Country/Region (2017-2022)
4.2.1 Global Novel Coronavirus Inactivated Vaccine Annual Sales by Country/Region (2017-2022)
4.2.2 Global Novel Coronavirus Inactivated Vaccine Annual Revenue by Country/Region
4.3 Americas Novel Coronavirus Inactivated Vaccine Sales Growth
4.4 APAC Novel Coronavirus Inactivated Vaccine Sales Growth
4.5 Europe Novel Coronavirus Inactivated Vaccine Sales Growth
4.6 Middle East & Africa Novel Coronavirus Inactivated Vaccine Sales Growth
5 AMERICAS
5.1 Americas Novel Coronavirus Inactivated Vaccine Sales by Country
5.1.1 Americas Novel Coronavirus Inactivated Vaccine Sales by Country (2017-2022)
5.1.2 Americas Novel Coronavirus Inactivated Vaccine Revenue by Country (2017-2022)
5.2 Americas Novel Coronavirus Inactivated Vaccine Sales by Type
5.3 Americas Novel Coronavirus Inactivated Vaccine Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Novel Coronavirus Inactivated Vaccine Sales by Region
6.1.1 APAC Novel Coronavirus Inactivated Vaccine Sales by Region (2017-2022)
6.1.2 APAC Novel Coronavirus Inactivated Vaccine Revenue by Region (2017-2022)
6.2 APAC Novel Coronavirus Inactivated Vaccine Sales by Type
6.3 APAC Novel Coronavirus Inactivated Vaccine Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Novel Coronavirus Inactivated Vaccine by Country
7.1.1 Europe Novel Coronavirus Inactivated Vaccine Sales by Country (2017-2022)
7.1.2 Europe Novel Coronavirus Inactivated Vaccine Revenue by Country (2017-2022)
7.2 Europe Novel Coronavirus Inactivated Vaccine Sales by Type
7.3 Europe Novel Coronavirus Inactivated Vaccine Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Novel Coronavirus Inactivated Vaccine by Country
8.1.1 Middle East & Africa Novel Coronavirus Inactivated Vaccine Sales by Country (2017-2022)
8.1.2 Middle East & Africa Novel Coronavirus Inactivated Vaccine Revenue by Country (2017-2022)
8.2 Middle East & Africa Novel Coronavirus Inactivated Vaccine Sales by Type
8.3 Middle East & Africa Novel Coronavirus Inactivated Vaccine Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Novel Coronavirus Inactivated Vaccine
10.3 Manufacturing Process Analysis of Novel Coronavirus Inactivated Vaccine
10.4 Industry Chain Structure of Novel Coronavirus Inactivated Vaccine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Novel Coronavirus Inactivated Vaccine Distributors
11.3 Novel Coronavirus Inactivated Vaccine Customer
12 WORLD FORECAST REVIEW FOR NOVEL CORONAVIRUS INACTIVATED VACCINE BY GEOGRAPHIC REGION
12.1 Global Novel Coronavirus Inactivated Vaccine Market Size Forecast by Region
12.1.1 Global Novel Coronavirus Inactivated Vaccine Forecast by Region (2023-2028)
12.1.2 Global Novel Coronavirus Inactivated Vaccine Annual Revenue Forecast by Region (2023-2028)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Novel Coronavirus Inactivated Vaccine Forecast by Type
12.7 Global Novel Coronavirus Inactivated Vaccine Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Inovio Pharmaceuticals
13.1.1 Inovio Pharmaceuticals Company Information
13.1.2 Inovio Pharmaceuticals Novel Coronavirus Inactivated Vaccine Product Offered
13.1.3 Inovio Pharmaceuticals Novel Coronavirus Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.1.4 Inovio Pharmaceuticals Main Business Overview
13.1.5 Inovio Pharmaceuticals Latest Developments
13.2 Moderna
13.2.1 Moderna Company Information
13.2.2 Moderna Novel Coronavirus Inactivated Vaccine Product Offered
13.2.3 Moderna Novel Coronavirus Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.2.4 Moderna Main Business Overview
13.2.5 Moderna Latest Developments
13.3 GlaxoSmithKine
13.3.1 GlaxoSmithKine Company Information
13.3.2 GlaxoSmithKine Novel Coronavirus Inactivated Vaccine Product Offered
13.3.3 GlaxoSmithKine Novel Coronavirus Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.3.4 GlaxoSmithKine Main Business Overview
13.3.5 GlaxoSmithKine Latest Developments
13.4 Pfizer
13.4.1 Pfizer Company Information
13.4.2 Pfizer Novel Coronavirus Inactivated Vaccine Product Offered
13.4.3 Pfizer Novel Coronavirus Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.4.4 Pfizer Main Business Overview
13.4.5 Pfizer Latest Developments
13.5 Johnson&Johnson
13.5.1 Johnson&Johnson Company Information
13.5.2 Johnson&Johnson Novel Coronavirus Inactivated Vaccine Product Offered
13.5.3 Johnson&Johnson Novel Coronavirus Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.5.4 Johnson&Johnson Main Business Overview
13.5.5 Johnson&Johnson Latest Developments
13.6 Heat Biologics
13.6.1 Heat Biologics Company Information
13.6.2 Heat Biologics Novel Coronavirus Inactivated Vaccine Product Offered
13.6.3 Heat Biologics Novel Coronavirus Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.6.4 Heat Biologics Main Business Overview
13.6.5 Heat Biologics Latest Developments
13.7 Sanofi
13.7.1 Sanofi Company Information
13.7.2 Sanofi Novel Coronavirus Inactivated Vaccine Product Offered
13.7.3 Sanofi Novel Coronavirus Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.7.4 Sanofi Main Business Overview
13.7.5 Sanofi Latest Developments
13.8 Beijing Institute of Biological Products Co., Ltd
13.8.1 Beijing Institute of Biological Products Co., Ltd Company Information
13.8.2 Beijing Institute of Biological Products Co., Ltd Novel Coronavirus Inactivated Vaccine Product Offered
13.8.3 Beijing Institute of Biological Products Co., Ltd Novel Coronavirus Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.8.4 Beijing Institute of Biological Products Co., Ltd Main Business Overview
13.8.5 Beijing Institute of Biological Products Co., Ltd Latest Developments
13.9 Beijing Kexing Zhongwei Biotechnology Co., Ltd
13.9.1 Beijing Kexing Zhongwei Biotechnology Co., Ltd Company Information
13.9.2 Beijing Kexing Zhongwei Biotechnology Co., Ltd Novel Coronavirus Inactivated Vaccine Product Offered
13.9.3 Beijing Kexing Zhongwei Biotechnology Co., Ltd Novel Coronavirus Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.9.4 Beijing Kexing Zhongwei Biotechnology Co., Ltd Main Business Overview
13.9.5 Beijing Kexing Zhongwei Biotechnology Co., Ltd Latest Developments
13.10 Shanghai Pharmaceutical CanSino Biopharmaceutical Co., Ltd
13.10.1 Shanghai Pharmaceutical CanSino Biopharmaceutical Co., Ltd Company Information
13.10.2 Shanghai Pharmaceutical CanSino Biopharmaceutical Co., Ltd Novel Coronavirus Inactivated Vaccine Product Offered
13.10.3 Shanghai Pharmaceutical CanSino Biopharmaceutical Co., Ltd Novel Coronavirus Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.10.4 Shanghai Pharmaceutical CanSino Biopharmaceutical Co., Ltd Main Business Overview
13.10.5 Shanghai Pharmaceutical CanSino Biopharmaceutical Co., Ltd Latest Developments
13.11 Wuhan Institute of Biological Products Co., Ltd
13.11.1 Wuhan Institute of Biological Products Co., Ltd Company Information
13.11.2 Wuhan Institute of Biological Products Co., Ltd Novel Coronavirus Inactivated Vaccine Product Offered
13.11.3 Wuhan Institute of Biological Products Co., Ltd Novel Coronavirus Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.11.4 Wuhan Institute of Biological Products Co., Ltd Main Business Overview
13.11.5 Wuhan Institute of Biological Products Co., Ltd Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Novel Coronavirus Inactivated Vaccine Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)
Table 2. Novel Coronavirus Inactivated Vaccine Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)
Table 3. Major Players of Adult
Table 4. Major Players of Child
Table 5. Global Novel Coronavirus Inactivated Vaccine Sales by Type (2017-2022) & (K Units)
Table 6. Global Novel Coronavirus Inactivated Vaccine Sales Market Share by Type (2017-2022)
Table 7. Global Novel Coronavirus Inactivated Vaccine Revenue by Type (2017-2022) & ($ million)
Table 8. Global Novel Coronavirus Inactivated Vaccine Revenue Market Share by Type (2017-2022)
Table 9. Global Novel Coronavirus Inactivated Vaccine Sale Price by Type (2017-2022) & (US$/Unit)
Table 10. Global Novel Coronavirus Inactivated Vaccine Sales by Application (2017-2022) & (K Units)
Table 11. Global Novel Coronavirus Inactivated Vaccine Sales Market Share by Application (2017-2022)
Table 12. Global Novel Coronavirus Inactivated Vaccine Revenue by Application (2017-2022)
Table 13. Global Novel Coronavirus Inactivated Vaccine Revenue Market Share by Application (2017-2022)
Table 14. Global Novel Coronavirus Inactivated Vaccine Sale Price by Application (2017-2022) & (US$/Unit)
Table 15. Global Novel Coronavirus Inactivated Vaccine Sales by Company (2020-2022) & (K Units)
Table 16. Global Novel Coronavirus Inactivated Vaccine Sales Market Share by Company (2020-2022)
Table 17. Global Novel Coronavirus Inactivated Vaccine Revenue by Company (2020-2022) ($ Millions)
Table 18. Global Novel Coronavirus Inactivated Vaccine Revenue Market Share by Company (2020-2022)
Table 19. Global Novel Coronavirus Inactivated Vaccine Sale Price by Company (2020-2022) & (US$/Unit)
Table 20. Key Manufacturers Novel Coronavirus Inactivated Vaccine Producing Area Distribution and Sales Area
Table 21. Players Novel Coronavirus Inactivated Vaccine Products Offered
Table 22. Novel Coronavirus Inactivated Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global Novel Coronavirus Inactivated Vaccine Sales by Geographic Region (2017-2022) & (K Units)
Table 26. Global Novel Coronavirus Inactivated Vaccine Sales Market Share Geographic Region (2017-2022)
Table 27. Global Novel Coronavirus Inactivated Vaccine Revenue by Geographic Region (2017-2022) & ($ millions)
Table 28. Global Novel Coronavirus Inactivated Vaccine Revenue Market Share by Geographic Region (2017-2022)
Table 29. Global Novel Coronavirus Inactivated Vaccine Sales by Country/Region (2017-2022) & (K Units)
Table 30. Global Novel Coronavirus Inactivated Vaccine Sales Market Share by Country/Region (2017-2022)
Table 31. Global Novel Coronavirus Inactivated Vaccine Revenue by Country/Region (2017-2022) & ($ millions)
Table 32. Global Novel Coronavirus Inactivated Vaccine Revenue Market Share by Country/Region (2017-2022)
Table 33. Americas Novel Coronavirus Inactivated Vaccine Sales by Country (2017-2022) & (K Units)
Table 34. Americas Novel Coronavirus Inactivated Vaccine Sales Market Share by Country (2017-2022)
Table 35. Americas Novel Coronavirus Inactivated Vaccine Revenue by Country (2017-2022) & ($ Millions)
Table 36. Americas Novel Coronavirus Inactivated Vaccine Revenue Market Share by Country (2017-2022)
Table 37. Americas Novel Coronavirus Inactivated Vaccine Sales by Type (2017-2022) & (K Units)
Table 38. Americas Novel Coronavirus Inactivated Vaccine Sales Market Share by Type (2017-2022)
Table 39. Americas Novel Coronavirus Inactivated Vaccine Sales by Application (2017-2022) & (K Units)
Table 40. Americas Novel Coronavirus Inactivated Vaccine Sales Market Share by Application (2017-2022)
Table 41. APAC Novel Coronavirus Inactivated Vaccine Sales by Region (2017-2022) & (K Units)
Table 42. APAC Novel Coronavirus Inactivated Vaccine Sales Market Share by Region (2017-2022)
Table 43. APAC Novel Coronavirus Inactivated Vaccine Revenue by Region (2017-2022) & ($ Millions)
Table 44. APAC Novel Coronavirus Inactivated Vaccine Revenue Market Share by Region (2017-2022)
Table 45. APAC Novel Coronavirus Inactivated Vaccine Sales by Type (2017-2022) & (K Units)
Table 46. APAC Novel Coronavirus Inactivated Vaccine Sales Market Share by Type (2017-2022)
Table 47. APAC Novel Coronavirus Inactivated Vaccine Sales by Application (2017-2022) & (K Units)
Table 48. APAC Novel Coronavirus Inactivated Vaccine Sales Market Share by Application (2017-2022)
Table 49. Europe Novel Coronavirus Inactivated Vaccine Sales by Country (2017-2022) & (K Units)
Table 50. Europe Novel Coronavirus Inactivated Vaccine Sales Market Share by Country (2017-2022)
Table 51. Europe Novel Coronavirus Inactivated Vaccine Revenue by Country (2017-2022) & ($ Millions)
Table 52. Europe Novel Coronavirus Inactivated Vaccine Revenue Market Share by Country (2017-2022)
Table 53. Europe Novel Coronavirus Inactivated Vaccine Sales by Type (2017-2022) & (K Units)
Table 54. Europe Novel Coronavirus Inactivated Vaccine Sales Market Share by Type (2017-2022)
Table 55. Europe Novel Coronavirus Inactivated Vaccine Sales by Application (2017-2022) & (K Units)
Table 56. Europe Novel Coronavirus Inactivated Vaccine Sales Market Share by Application (2017-2022)
Table 57. Middle East & Africa Novel Coronavirus Inactivated Vaccine Sales by Country (2017-2022) & (K Units)
Table 58. Middle East & Africa Novel Coronavirus Inactivated Vaccine Sales Market Share by Country (2017-2022)
Table 59. Middle East & Africa Novel Coronavirus Inactivated Vaccine Revenue by Country (2017-2022) & ($ Millions)
Table 60. Middle East & Africa Novel Coronavirus Inactivated Vaccine Revenue Market Share by Country (2017-2022)
Table 61. Middle East & Africa Novel Coronavirus Inactivated Vaccine Sales by Type (2017-2022) & (K Units)
Table 62. Middle East & Africa Novel Coronavirus Inactivated Vaccine Sales Market Share by Type (2017-2022)
Table 63. Middle East & Africa Novel Coronavirus Inactivated Vaccine Sales by Application (2017-2022) & (K Units)
Table 64. Middle East & Africa Novel Coronavirus Inactivated Vaccine Sales Market Share by Application (2017-2022)
Table 65. Key Market Drivers & Growth Opportunities of Novel Coronavirus Inactivated Vaccine
Table 66. Key Market Challenges & Risks of Novel Coronavirus Inactivated Vaccine
Table 67. Key Industry Trends of Novel Coronavirus Inactivated Vaccine
Table 68. Novel Coronavirus Inactivated Vaccine Raw Material
Table 69. Key Suppliers of Raw Materials
Table 70. Novel Coronavirus Inactivated Vaccine Distributors List
Table 71. Novel Coronavirus Inactivated Vaccine Customer List
Table 72. Global Novel Coronavirus Inactivated Vaccine Sales Forecast by Region (2023-2028) & (K Units)
Table 73. Global Novel Coronavirus Inactivated Vaccine Sales Market Forecast by Region
Table 74. Global Novel Coronavirus Inactivated Vaccine Revenue Forecast by Region (2023-2028) & ($ millions)
Table 75. Global Novel Coronavirus Inactivated Vaccine Revenue Market Share Forecast by Region (2023-2028)
Table 76. Americas Novel Coronavirus Inactivated Vaccine Sales Forecast by Country (2023-2028) & (K Units)
Table 77. Americas Novel Coronavirus Inactivated Vaccine Revenue Forecast by Country (2023-2028) & ($ millions)
Table 78. APAC Novel Coronavirus Inactivated Vaccine Sales Forecast by Region (2023-2028) & (K Units)
Table 79. APAC Novel Coronavirus Inactivated Vaccine Revenue Forecast by Region (2023-2028) & ($ millions)
Table 80. Europe Novel Coronavirus Inactivated Vaccine Sales Forecast by Country (2023-2028) & (K Units)
Table 81. Europe Novel Coronavirus Inactivated Vaccine Revenue Forecast by Country (2023-2028) & ($ millions)
Table 82. Middle East & Africa Novel Coronavirus Inactivated Vaccine Sales Forecast by Country (2023-2028) & (K Units)
Table 83. Middle East & Africa Novel Coronavirus Inactivated Vaccine Revenue Forecast by Country (2023-2028) & ($ millions)
Table 84. Global Novel Coronavirus Inactivated Vaccine Sales Forecast by Type (2023-2028) & (K Units)
Table 85. Global Novel Coronavirus Inactivated Vaccine Sales Market Share Forecast by Type (2023-2028)
Table 86. Global Novel Coronavirus Inactivated Vaccine Revenue Forecast by Type (2023-2028) & ($ Millions)
Table 87. Global Novel Coronavirus Inactivated Vaccine Revenue Market Share Forecast by Type (2023-2028)
Table 88. Global Novel Coronavirus Inactivated Vaccine Sales Forecast by Application (2023-2028) & (K Units)
Table 89. Global Novel Coronavirus Inactivated Vaccine Sales Market Share Forecast by Application (2023-2028)
Table 90. Global Novel Coronavirus Inactivated Vaccine Revenue Forecast by Application (2023-2028) & ($ Millions)
Table 91. Global Novel Coronavirus Inactivated Vaccine Revenue Market Share Forecast by Application (2023-2028)
Table 92. Inovio Pharmaceuticals Basic Information, Novel Coronavirus Inactivated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 93. Inovio Pharmaceuticals Novel Coronavirus Inactivated Vaccine Product Offered
Table 94. Inovio Pharmaceuticals Novel Coronavirus Inactivated Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 95. Inovio Pharmaceuticals Main Business
Table 96. Inovio Pharmaceuticals Latest Developments
Table 97. Moderna Basic Information, Novel Coronavirus Inactivated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 98. Moderna Novel Coronavirus Inactivated Vaccine Product Offered
Table 99. Moderna Novel Coronavirus Inactivated Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 100. Moderna Main Business
Table 101. Moderna Latest Developments
Table 102. GlaxoSmithKine Basic Information, Novel Coronavirus Inactivated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 103. GlaxoSmithKine Novel Coronavirus Inactivated Vaccine Product Offered
Table 104. GlaxoSmithKine Novel Coronavirus Inactivated Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 105. GlaxoSmithKine Main Business
Table 106. GlaxoSmithKine Latest Developments
Table 107. Pfizer Basic Information, Novel Coronavirus Inactivated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 108. Pfizer Novel Coronavirus Inactivated Vaccine Product Offered
Table 109. Pfizer Novel Coronavirus Inactivated Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 110. Pfizer Main Business
Table 111. Pfizer Latest Developments
Table 112. Johnson&Johnson Basic Information, Novel Coronavirus Inactivated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 113. Johnson&Johnson Novel Coronavirus Inactivated Vaccine Product Offered
Table 114. Johnson&Johnson Novel Coronavirus Inactivated Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 115. Johnson&Johnson Main Business
Table 116. Johnson&Johnson Latest Developments
Table 117. Heat Biologics Basic Information, Novel Coronavirus Inactivated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 118. Heat Biologics Novel Coronavirus Inactivated Vaccine Product Offered
Table 119. Heat Biologics Novel Coronavirus Inactivated Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 120. Heat Biologics Main Business
Table 121. Heat Biologics Latest Developments
Table 122. Sanofi Basic Information, Novel Coronavirus Inactivated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 123. Sanofi Novel Coronavirus Inactivated Vaccine Product Offered
Table 124. Sanofi Novel Coronavirus Inactivated Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 125. Sanofi Main Business
Table 126. Sanofi Latest Developments
Table 127. Beijing Institute of Biological Products Co., Ltd Basic Information, Novel Coronavirus Inactivated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 128. Beijing Institute of Biological Products Co., Ltd Novel Coronavirus Inactivated Vaccine Product Offered
Table 129. Beijing Institute of Biological Products Co., Ltd Novel Coronavirus Inactivated Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 130. Beijing Institute of Biological Products Co., Ltd Main Business
Table 131. Beijing Institute of Biological Products Co., Ltd Latest Developments
Table 132. Beijing Kexing Zhongwei Biotechnology Co., Ltd Basic Information, Novel Coronavirus Inactivated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 133. Beijing Kexing Zhongwei Biotechnology Co., Ltd Novel Coronavirus Inactivated Vaccine Product Offered
Table 134. Beijing Kexing Zhongwei Biotechnology Co., Ltd Novel Coronavirus Inactivated Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 135. Beijing Kexing Zhongwei Biotechnology Co., Ltd Main Business
Table 136. Beijing Kexing Zhongwei Biotechnology Co., Ltd Latest Developments
Table 137. Shanghai Pharmaceutical CanSino Biopharmaceutical Co., Ltd Basic Information, Novel Coronavirus Inactivated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 138. Shanghai Pharmaceutical CanSino Biopharmaceutical Co., Ltd Novel Coronavirus Inactivated Vaccine Product Offered
Table 139. Shanghai Pharmaceutical CanSino Biopharmaceutical Co., Ltd Novel Coronavirus Inactivated Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 140. Shanghai Pharmaceutical CanSino Biopharmaceutical Co., Ltd Main Business
Table 141. Shanghai Pharmaceutical CanSino Biopharmaceutical Co., Ltd Latest Developments
Table 142. Wuhan Institute of Biological Products Co., Ltd Basic Information, Novel Coronavirus Inactivated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 143. Wuhan Institute of Biological Products Co., Ltd Novel Coronavirus Inactivated Vaccine Product Offered
Table 144. Wuhan Institute of Biological Products Co., Ltd Novel Coronavirus Inactivated Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 145. Wuhan Institute of Biological Products Co., Ltd Main Business
Table 146. Wuhan Institute of Biological Products Co., Ltd Latest Developments
Table 1. Novel Coronavirus Inactivated Vaccine Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)
Table 2. Novel Coronavirus Inactivated Vaccine Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)
Table 3. Major Players of Adult
Table 4. Major Players of Child
Table 5. Global Novel Coronavirus Inactivated Vaccine Sales by Type (2017-2022) & (K Units)
Table 6. Global Novel Coronavirus Inactivated Vaccine Sales Market Share by Type (2017-2022)
Table 7. Global Novel Coronavirus Inactivated Vaccine Revenue by Type (2017-2022) & ($ million)
Table 8. Global Novel Coronavirus Inactivated Vaccine Revenue Market Share by Type (2017-2022)
Table 9. Global Novel Coronavirus Inactivated Vaccine Sale Price by Type (2017-2022) & (US$/Unit)
Table 10. Global Novel Coronavirus Inactivated Vaccine Sales by Application (2017-2022) & (K Units)
Table 11. Global Novel Coronavirus Inactivated Vaccine Sales Market Share by Application (2017-2022)
Table 12. Global Novel Coronavirus Inactivated Vaccine Revenue by Application (2017-2022)
Table 13. Global Novel Coronavirus Inactivated Vaccine Revenue Market Share by Application (2017-2022)
Table 14. Global Novel Coronavirus Inactivated Vaccine Sale Price by Application (2017-2022) & (US$/Unit)
Table 15. Global Novel Coronavirus Inactivated Vaccine Sales by Company (2020-2022) & (K Units)
Table 16. Global Novel Coronavirus Inactivated Vaccine Sales Market Share by Company (2020-2022)
Table 17. Global Novel Coronavirus Inactivated Vaccine Revenue by Company (2020-2022) ($ Millions)
Table 18. Global Novel Coronavirus Inactivated Vaccine Revenue Market Share by Company (2020-2022)
Table 19. Global Novel Coronavirus Inactivated Vaccine Sale Price by Company (2020-2022) & (US$/Unit)
Table 20. Key Manufacturers Novel Coronavirus Inactivated Vaccine Producing Area Distribution and Sales Area
Table 21. Players Novel Coronavirus Inactivated Vaccine Products Offered
Table 22. Novel Coronavirus Inactivated Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global Novel Coronavirus Inactivated Vaccine Sales by Geographic Region (2017-2022) & (K Units)
Table 26. Global Novel Coronavirus Inactivated Vaccine Sales Market Share Geographic Region (2017-2022)
Table 27. Global Novel Coronavirus Inactivated Vaccine Revenue by Geographic Region (2017-2022) & ($ millions)
Table 28. Global Novel Coronavirus Inactivated Vaccine Revenue Market Share by Geographic Region (2017-2022)
Table 29. Global Novel Coronavirus Inactivated Vaccine Sales by Country/Region (2017-2022) & (K Units)
Table 30. Global Novel Coronavirus Inactivated Vaccine Sales Market Share by Country/Region (2017-2022)
Table 31. Global Novel Coronavirus Inactivated Vaccine Revenue by Country/Region (2017-2022) & ($ millions)
Table 32. Global Novel Coronavirus Inactivated Vaccine Revenue Market Share by Country/Region (2017-2022)
Table 33. Americas Novel Coronavirus Inactivated Vaccine Sales by Country (2017-2022) & (K Units)
Table 34. Americas Novel Coronavirus Inactivated Vaccine Sales Market Share by Country (2017-2022)
Table 35. Americas Novel Coronavirus Inactivated Vaccine Revenue by Country (2017-2022) & ($ Millions)
Table 36. Americas Novel Coronavirus Inactivated Vaccine Revenue Market Share by Country (2017-2022)
Table 37. Americas Novel Coronavirus Inactivated Vaccine Sales by Type (2017-2022) & (K Units)
Table 38. Americas Novel Coronavirus Inactivated Vaccine Sales Market Share by Type (2017-2022)
Table 39. Americas Novel Coronavirus Inactivated Vaccine Sales by Application (2017-2022) & (K Units)
Table 40. Americas Novel Coronavirus Inactivated Vaccine Sales Market Share by Application (2017-2022)
Table 41. APAC Novel Coronavirus Inactivated Vaccine Sales by Region (2017-2022) & (K Units)
Table 42. APAC Novel Coronavirus Inactivated Vaccine Sales Market Share by Region (2017-2022)
Table 43. APAC Novel Coronavirus Inactivated Vaccine Revenue by Region (2017-2022) & ($ Millions)
Table 44. APAC Novel Coronavirus Inactivated Vaccine Revenue Market Share by Region (2017-2022)
Table 45. APAC Novel Coronavirus Inactivated Vaccine Sales by Type (2017-2022) & (K Units)
Table 46. APAC Novel Coronavirus Inactivated Vaccine Sales Market Share by Type (2017-2022)
Table 47. APAC Novel Coronavirus Inactivated Vaccine Sales by Application (2017-2022) & (K Units)
Table 48. APAC Novel Coronavirus Inactivated Vaccine Sales Market Share by Application (2017-2022)
Table 49. Europe Novel Coronavirus Inactivated Vaccine Sales by Country (2017-2022) & (K Units)
Table 50. Europe Novel Coronavirus Inactivated Vaccine Sales Market Share by Country (2017-2022)
Table 51. Europe Novel Coronavirus Inactivated Vaccine Revenue by Country (2017-2022) & ($ Millions)
Table 52. Europe Novel Coronavirus Inactivated Vaccine Revenue Market Share by Country (2017-2022)
Table 53. Europe Novel Coronavirus Inactivated Vaccine Sales by Type (2017-2022) & (K Units)
Table 54. Europe Novel Coronavirus Inactivated Vaccine Sales Market Share by Type (2017-2022)
Table 55. Europe Novel Coronavirus Inactivated Vaccine Sales by Application (2017-2022) & (K Units)
Table 56. Europe Novel Coronavirus Inactivated Vaccine Sales Market Share by Application (2017-2022)
Table 57. Middle East & Africa Novel Coronavirus Inactivated Vaccine Sales by Country (2017-2022) & (K Units)
Table 58. Middle East & Africa Novel Coronavirus Inactivated Vaccine Sales Market Share by Country (2017-2022)
Table 59. Middle East & Africa Novel Coronavirus Inactivated Vaccine Revenue by Country (2017-2022) & ($ Millions)
Table 60. Middle East & Africa Novel Coronavirus Inactivated Vaccine Revenue Market Share by Country (2017-2022)
Table 61. Middle East & Africa Novel Coronavirus Inactivated Vaccine Sales by Type (2017-2022) & (K Units)
Table 62. Middle East & Africa Novel Coronavirus Inactivated Vaccine Sales Market Share by Type (2017-2022)
Table 63. Middle East & Africa Novel Coronavirus Inactivated Vaccine Sales by Application (2017-2022) & (K Units)
Table 64. Middle East & Africa Novel Coronavirus Inactivated Vaccine Sales Market Share by Application (2017-2022)
Table 65. Key Market Drivers & Growth Opportunities of Novel Coronavirus Inactivated Vaccine
Table 66. Key Market Challenges & Risks of Novel Coronavirus Inactivated Vaccine
Table 67. Key Industry Trends of Novel Coronavirus Inactivated Vaccine
Table 68. Novel Coronavirus Inactivated Vaccine Raw Material
Table 69. Key Suppliers of Raw Materials
Table 70. Novel Coronavirus Inactivated Vaccine Distributors List
Table 71. Novel Coronavirus Inactivated Vaccine Customer List
Table 72. Global Novel Coronavirus Inactivated Vaccine Sales Forecast by Region (2023-2028) & (K Units)
Table 73. Global Novel Coronavirus Inactivated Vaccine Sales Market Forecast by Region
Table 74. Global Novel Coronavirus Inactivated Vaccine Revenue Forecast by Region (2023-2028) & ($ millions)
Table 75. Global Novel Coronavirus Inactivated Vaccine Revenue Market Share Forecast by Region (2023-2028)
Table 76. Americas Novel Coronavirus Inactivated Vaccine Sales Forecast by Country (2023-2028) & (K Units)
Table 77. Americas Novel Coronavirus Inactivated Vaccine Revenue Forecast by Country (2023-2028) & ($ millions)
Table 78. APAC Novel Coronavirus Inactivated Vaccine Sales Forecast by Region (2023-2028) & (K Units)
Table 79. APAC Novel Coronavirus Inactivated Vaccine Revenue Forecast by Region (2023-2028) & ($ millions)
Table 80. Europe Novel Coronavirus Inactivated Vaccine Sales Forecast by Country (2023-2028) & (K Units)
Table 81. Europe Novel Coronavirus Inactivated Vaccine Revenue Forecast by Country (2023-2028) & ($ millions)
Table 82. Middle East & Africa Novel Coronavirus Inactivated Vaccine Sales Forecast by Country (2023-2028) & (K Units)
Table 83. Middle East & Africa Novel Coronavirus Inactivated Vaccine Revenue Forecast by Country (2023-2028) & ($ millions)
Table 84. Global Novel Coronavirus Inactivated Vaccine Sales Forecast by Type (2023-2028) & (K Units)
Table 85. Global Novel Coronavirus Inactivated Vaccine Sales Market Share Forecast by Type (2023-2028)
Table 86. Global Novel Coronavirus Inactivated Vaccine Revenue Forecast by Type (2023-2028) & ($ Millions)
Table 87. Global Novel Coronavirus Inactivated Vaccine Revenue Market Share Forecast by Type (2023-2028)
Table 88. Global Novel Coronavirus Inactivated Vaccine Sales Forecast by Application (2023-2028) & (K Units)
Table 89. Global Novel Coronavirus Inactivated Vaccine Sales Market Share Forecast by Application (2023-2028)
Table 90. Global Novel Coronavirus Inactivated Vaccine Revenue Forecast by Application (2023-2028) & ($ Millions)
Table 91. Global Novel Coronavirus Inactivated Vaccine Revenue Market Share Forecast by Application (2023-2028)
Table 92. Inovio Pharmaceuticals Basic Information, Novel Coronavirus Inactivated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 93. Inovio Pharmaceuticals Novel Coronavirus Inactivated Vaccine Product Offered
Table 94. Inovio Pharmaceuticals Novel Coronavirus Inactivated Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 95. Inovio Pharmaceuticals Main Business
Table 96. Inovio Pharmaceuticals Latest Developments
Table 97. Moderna Basic Information, Novel Coronavirus Inactivated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 98. Moderna Novel Coronavirus Inactivated Vaccine Product Offered
Table 99. Moderna Novel Coronavirus Inactivated Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 100. Moderna Main Business
Table 101. Moderna Latest Developments
Table 102. GlaxoSmithKine Basic Information, Novel Coronavirus Inactivated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 103. GlaxoSmithKine Novel Coronavirus Inactivated Vaccine Product Offered
Table 104. GlaxoSmithKine Novel Coronavirus Inactivated Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 105. GlaxoSmithKine Main Business
Table 106. GlaxoSmithKine Latest Developments
Table 107. Pfizer Basic Information, Novel Coronavirus Inactivated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 108. Pfizer Novel Coronavirus Inactivated Vaccine Product Offered
Table 109. Pfizer Novel Coronavirus Inactivated Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 110. Pfizer Main Business
Table 111. Pfizer Latest Developments
Table 112. Johnson&Johnson Basic Information, Novel Coronavirus Inactivated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 113. Johnson&Johnson Novel Coronavirus Inactivated Vaccine Product Offered
Table 114. Johnson&Johnson Novel Coronavirus Inactivated Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 115. Johnson&Johnson Main Business
Table 116. Johnson&Johnson Latest Developments
Table 117. Heat Biologics Basic Information, Novel Coronavirus Inactivated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 118. Heat Biologics Novel Coronavirus Inactivated Vaccine Product Offered
Table 119. Heat Biologics Novel Coronavirus Inactivated Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 120. Heat Biologics Main Business
Table 121. Heat Biologics Latest Developments
Table 122. Sanofi Basic Information, Novel Coronavirus Inactivated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 123. Sanofi Novel Coronavirus Inactivated Vaccine Product Offered
Table 124. Sanofi Novel Coronavirus Inactivated Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 125. Sanofi Main Business
Table 126. Sanofi Latest Developments
Table 127. Beijing Institute of Biological Products Co., Ltd Basic Information, Novel Coronavirus Inactivated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 128. Beijing Institute of Biological Products Co., Ltd Novel Coronavirus Inactivated Vaccine Product Offered
Table 129. Beijing Institute of Biological Products Co., Ltd Novel Coronavirus Inactivated Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 130. Beijing Institute of Biological Products Co., Ltd Main Business
Table 131. Beijing Institute of Biological Products Co., Ltd Latest Developments
Table 132. Beijing Kexing Zhongwei Biotechnology Co., Ltd Basic Information, Novel Coronavirus Inactivated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 133. Beijing Kexing Zhongwei Biotechnology Co., Ltd Novel Coronavirus Inactivated Vaccine Product Offered
Table 134. Beijing Kexing Zhongwei Biotechnology Co., Ltd Novel Coronavirus Inactivated Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 135. Beijing Kexing Zhongwei Biotechnology Co., Ltd Main Business
Table 136. Beijing Kexing Zhongwei Biotechnology Co., Ltd Latest Developments
Table 137. Shanghai Pharmaceutical CanSino Biopharmaceutical Co., Ltd Basic Information, Novel Coronavirus Inactivated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 138. Shanghai Pharmaceutical CanSino Biopharmaceutical Co., Ltd Novel Coronavirus Inactivated Vaccine Product Offered
Table 139. Shanghai Pharmaceutical CanSino Biopharmaceutical Co., Ltd Novel Coronavirus Inactivated Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 140. Shanghai Pharmaceutical CanSino Biopharmaceutical Co., Ltd Main Business
Table 141. Shanghai Pharmaceutical CanSino Biopharmaceutical Co., Ltd Latest Developments
Table 142. Wuhan Institute of Biological Products Co., Ltd Basic Information, Novel Coronavirus Inactivated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 143. Wuhan Institute of Biological Products Co., Ltd Novel Coronavirus Inactivated Vaccine Product Offered
Table 144. Wuhan Institute of Biological Products Co., Ltd Novel Coronavirus Inactivated Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 145. Wuhan Institute of Biological Products Co., Ltd Main Business
Table 146. Wuhan Institute of Biological Products Co., Ltd Latest Developments
LIST OF FIGURES
Figure 1. Picture of Novel Coronavirus Inactivated Vaccine
Figure 2. Novel Coronavirus Inactivated Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Novel Coronavirus Inactivated Vaccine Sales Growth Rate 2017-2028 (K Units)
Figure 7. Global Novel Coronavirus Inactivated Vaccine Revenue Growth Rate 2017-2028 ($ Millions)
Figure 8. Novel Coronavirus Inactivated Vaccine Sales by Region (2021 & 2028) & ($ millions)
Figure 9. Product Picture of Adult
Figure 10. Product Picture of Child
Figure 11. Global Novel Coronavirus Inactivated Vaccine Sales Market Share by Type in 2021
Figure 12. Global Novel Coronavirus Inactivated Vaccine Revenue Market Share by Type (2017-2022)
Figure 13. Novel Coronavirus Inactivated Vaccine Consumed in Hospital
Figure 14. Global Novel Coronavirus Inactivated Vaccine Market: Hospital (2017-2022) & (K Units)
Figure 15. Novel Coronavirus Inactivated Vaccine Consumed in Clinic
Figure 16. Global Novel Coronavirus Inactivated Vaccine Market: Clinic (2017-2022) & (K Units)
Figure 17. Global Novel Coronavirus Inactivated Vaccine Sales Market Share by Application (2017-2022)
Figure 18. Global Novel Coronavirus Inactivated Vaccine Revenue Market Share by Application in 2021
Figure 19. Novel Coronavirus Inactivated Vaccine Revenue Market by Company in 2021 ($ Million)
Figure 20. Global Novel Coronavirus Inactivated Vaccine Revenue Market Share by Company in 2021
Figure 21. Global Novel Coronavirus Inactivated Vaccine Sales Market Share by Geographic Region (2017-2022)
Figure 22. Global Novel Coronavirus Inactivated Vaccine Revenue Market Share by Geographic Region in 2021
Figure 23. Global Novel Coronavirus Inactivated Vaccine Sales Market Share by Region (2017-2022)
Figure 24. Global Novel Coronavirus Inactivated Vaccine Revenue Market Share by Country/Region in 2021
Figure 25. Americas Novel Coronavirus Inactivated Vaccine Sales 2017-2022 (K Units)
Figure 26. Americas Novel Coronavirus Inactivated Vaccine Revenue 2017-2022 ($ Millions)
Figure 27. APAC Novel Coronavirus Inactivated Vaccine Sales 2017-2022 (K Units)
Figure 28. APAC Novel Coronavirus Inactivated Vaccine Revenue 2017-2022 ($ Millions)
Figure 29. Europe Novel Coronavirus Inactivated Vaccine Sales 2017-2022 (K Units)
Figure 30. Europe Novel Coronavirus Inactivated Vaccine Revenue 2017-2022 ($ Millions)
Figure 31. Middle East & Africa Novel Coronavirus Inactivated Vaccine Sales 2017-2022 (K Units)
Figure 32. Middle East & Africa Novel Coronavirus Inactivated Vaccine Revenue 2017-2022 ($ Millions)
Figure 33. Americas Novel Coronavirus Inactivated Vaccine Sales Market Share by Country in 2021
Figure 34. Americas Novel Coronavirus Inactivated Vaccine Revenue Market Share by Country in 2021
Figure 35. United States Novel Coronavirus Inactivated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 36. Canada Novel Coronavirus Inactivated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 37. Mexico Novel Coronavirus Inactivated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 38. Brazil Novel Coronavirus Inactivated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 39. APAC Novel Coronavirus Inactivated Vaccine Sales Market Share by Region in 2021
Figure 40. APAC Novel Coronavirus Inactivated Vaccine Revenue Market Share by Regions in 2021
Figure 41. China Novel Coronavirus Inactivated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 42. Japan Novel Coronavirus Inactivated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 43. South Korea Novel Coronavirus Inactivated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 44. Southeast Asia Novel Coronavirus Inactivated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 45. India Novel Coronavirus Inactivated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 46. Australia Novel Coronavirus Inactivated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 47. Europe Novel Coronavirus Inactivated Vaccine Sales Market Share by Country in 2021
Figure 48. Europe Novel Coronavirus Inactivated Vaccine Revenue Market Share by Country in 2021
Figure 49. Germany Novel Coronavirus Inactivated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 50. France Novel Coronavirus Inactivated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 51. UK Novel Coronavirus Inactivated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 52. Italy Novel Coronavirus Inactivated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 53. Russia Novel Coronavirus Inactivated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 54. Middle East & Africa Novel Coronavirus Inactivated Vaccine Sales Market Share by Country in 2021
Figure 55. Middle East & Africa Novel Coronavirus Inactivated Vaccine Revenue Market Share by Country in 2021
Figure 56. Egypt Novel Coronavirus Inactivated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 57. South Africa Novel Coronavirus Inactivated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 58. Israel Novel Coronavirus Inactivated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 59. Turkey Novel Coronavirus Inactivated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 60. GCC Country Novel Coronavirus Inactivated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 61. Manufacturing Cost Structure Analysis of Novel Coronavirus Inactivated Vaccine in 2021
Figure 62. Manufacturing Process Analysis of Novel Coronavirus Inactivated Vaccine
Figure 63. Industry Chain Structure of Novel Coronavirus Inactivated Vaccine
Figure 64. Channels of Distribution
Figure 65. Distributors Profiles
Figure 1. Picture of Novel Coronavirus Inactivated Vaccine
Figure 2. Novel Coronavirus Inactivated Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Novel Coronavirus Inactivated Vaccine Sales Growth Rate 2017-2028 (K Units)
Figure 7. Global Novel Coronavirus Inactivated Vaccine Revenue Growth Rate 2017-2028 ($ Millions)
Figure 8. Novel Coronavirus Inactivated Vaccine Sales by Region (2021 & 2028) & ($ millions)
Figure 9. Product Picture of Adult
Figure 10. Product Picture of Child
Figure 11. Global Novel Coronavirus Inactivated Vaccine Sales Market Share by Type in 2021
Figure 12. Global Novel Coronavirus Inactivated Vaccine Revenue Market Share by Type (2017-2022)
Figure 13. Novel Coronavirus Inactivated Vaccine Consumed in Hospital
Figure 14. Global Novel Coronavirus Inactivated Vaccine Market: Hospital (2017-2022) & (K Units)
Figure 15. Novel Coronavirus Inactivated Vaccine Consumed in Clinic
Figure 16. Global Novel Coronavirus Inactivated Vaccine Market: Clinic (2017-2022) & (K Units)
Figure 17. Global Novel Coronavirus Inactivated Vaccine Sales Market Share by Application (2017-2022)
Figure 18. Global Novel Coronavirus Inactivated Vaccine Revenue Market Share by Application in 2021
Figure 19. Novel Coronavirus Inactivated Vaccine Revenue Market by Company in 2021 ($ Million)
Figure 20. Global Novel Coronavirus Inactivated Vaccine Revenue Market Share by Company in 2021
Figure 21. Global Novel Coronavirus Inactivated Vaccine Sales Market Share by Geographic Region (2017-2022)
Figure 22. Global Novel Coronavirus Inactivated Vaccine Revenue Market Share by Geographic Region in 2021
Figure 23. Global Novel Coronavirus Inactivated Vaccine Sales Market Share by Region (2017-2022)
Figure 24. Global Novel Coronavirus Inactivated Vaccine Revenue Market Share by Country/Region in 2021
Figure 25. Americas Novel Coronavirus Inactivated Vaccine Sales 2017-2022 (K Units)
Figure 26. Americas Novel Coronavirus Inactivated Vaccine Revenue 2017-2022 ($ Millions)
Figure 27. APAC Novel Coronavirus Inactivated Vaccine Sales 2017-2022 (K Units)
Figure 28. APAC Novel Coronavirus Inactivated Vaccine Revenue 2017-2022 ($ Millions)
Figure 29. Europe Novel Coronavirus Inactivated Vaccine Sales 2017-2022 (K Units)
Figure 30. Europe Novel Coronavirus Inactivated Vaccine Revenue 2017-2022 ($ Millions)
Figure 31. Middle East & Africa Novel Coronavirus Inactivated Vaccine Sales 2017-2022 (K Units)
Figure 32. Middle East & Africa Novel Coronavirus Inactivated Vaccine Revenue 2017-2022 ($ Millions)
Figure 33. Americas Novel Coronavirus Inactivated Vaccine Sales Market Share by Country in 2021
Figure 34. Americas Novel Coronavirus Inactivated Vaccine Revenue Market Share by Country in 2021
Figure 35. United States Novel Coronavirus Inactivated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 36. Canada Novel Coronavirus Inactivated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 37. Mexico Novel Coronavirus Inactivated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 38. Brazil Novel Coronavirus Inactivated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 39. APAC Novel Coronavirus Inactivated Vaccine Sales Market Share by Region in 2021
Figure 40. APAC Novel Coronavirus Inactivated Vaccine Revenue Market Share by Regions in 2021
Figure 41. China Novel Coronavirus Inactivated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 42. Japan Novel Coronavirus Inactivated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 43. South Korea Novel Coronavirus Inactivated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 44. Southeast Asia Novel Coronavirus Inactivated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 45. India Novel Coronavirus Inactivated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 46. Australia Novel Coronavirus Inactivated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 47. Europe Novel Coronavirus Inactivated Vaccine Sales Market Share by Country in 2021
Figure 48. Europe Novel Coronavirus Inactivated Vaccine Revenue Market Share by Country in 2021
Figure 49. Germany Novel Coronavirus Inactivated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 50. France Novel Coronavirus Inactivated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 51. UK Novel Coronavirus Inactivated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 52. Italy Novel Coronavirus Inactivated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 53. Russia Novel Coronavirus Inactivated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 54. Middle East & Africa Novel Coronavirus Inactivated Vaccine Sales Market Share by Country in 2021
Figure 55. Middle East & Africa Novel Coronavirus Inactivated Vaccine Revenue Market Share by Country in 2021
Figure 56. Egypt Novel Coronavirus Inactivated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 57. South Africa Novel Coronavirus Inactivated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 58. Israel Novel Coronavirus Inactivated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 59. Turkey Novel Coronavirus Inactivated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 60. GCC Country Novel Coronavirus Inactivated Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 61. Manufacturing Cost Structure Analysis of Novel Coronavirus Inactivated Vaccine in 2021
Figure 62. Manufacturing Process Analysis of Novel Coronavirus Inactivated Vaccine
Figure 63. Industry Chain Structure of Novel Coronavirus Inactivated Vaccine
Figure 64. Channels of Distribution
Figure 65. Distributors Profiles
